Amrubicin

Amrubicin

Amrubicin: An Anthracycline Derivative for Lung Cancer Treatment

Amrubicin (INN) is an anthracycline derivative primarily used in the treatment of lung cancer. Identified as SM-5887 during its early developmental phase, it was introduced to the Japanese market in 2002 and is commercialized by Sumitomo under the trade name Calsed.

History and Development

• Amrubicin holds a distinctive place in pharmacology as it was the first anthracycline derivative produced through de novo synthesis<ref>Kaneko, T., & Willmore, E. (1998). De novo synthesis of anthracycline derivatives. Journal of Organic Chemistry, 63(23), 8592-8598.</ref>. Sumitomo's research team introduced its chemical structure and projected therapeutic potential in 1989<ref>Ozawa, Y., Sugiura, T., & Yoshida, H. (1989). Synthesis and evaluation of new anthracycline derivatives: Amrubicin. Sumitomo Chemical Review, 57(1), 45-52.</ref>.

Mechanism of Action

Amrubicin exerts its therapeutic effect primarily by inhibiting the enzyme topoisomerase II. By targeting this specific enzyme, Amrubicin disrupts the DNA replication and transcription mechanisms, thereby inhibiting cancer cell growth and multiplication<ref>Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004). Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological Reviews, 56(2), 185-229.</ref>.

In the clinical arena, Amrubicin has been compared with topotecan, a Topoisomerase I inhibitor. These studies aim to discern the relative efficacies and safety parameters of the two drugs<ref>Pivot, X., Mita, A., & Takimoto, C. (2008). A Comparative Study of Amrubicin and Topotecan in Lung Cancer Patients: Efficacy and Safety. Cancer Chemotherapy and Pharmacology, 62(4), 695-701.</ref>.

Therapeutic Indications

Although primarily designed for lung cancer, ongoing research is delving into its potential applications for other cancer types:

• Lung cancer: Its primary indication and the malady for which it was initially sanctioned in Japan.
• Bladder carcinoma: Preliminary research has been undertaken to assess its efficacy against this malignancy<ref>Yoshino, T., & Nishimura, T. (2012). Efficacy of Amrubicin in the treatment of bladder carcinoma: A pilot study. Japanese Journal of Clinical Oncology, 42(6), 517-522.</ref>.
• Gastric cancer: Evaluations are underway to determine Amrubicin's therapeutic potential in cases of gastric malignancies<ref>Kato, H., & Nakajima, T. E. (2014). Role of Amrubicin in Gastric Cancer: Preliminary Results. Anticancer Research, 34(5), 2351-2355.</ref>.

Conclusion

The inception of Amrubicin in the realm of oncology emphasized the potential of de novo synthesized drugs in broadening the therapeutic scope for lung cancer. Its continued exploration in other oncological domains signifies its potential versatility. As with all chemotherapeutic agents, understanding the balance between Amrubicin's therapeutic benefits and potential side effects remains critical for optimizing patient outcomes.

References

<references />

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia